Abstract
Ipilimumab is a fully human monoclonal antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4). It is intended to be used as a drug to activate the immune system by binding to CTLA-4, which suppresses T-cells in natural immune responses. Recently, a phase III, multi-center, randomized, double-blind, clinical study showed an improvement in over-all/progression-free survival in patients with advanced melanomas. Ipilimumab is undergoing clinical trials for the treatment of melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and metastatic hormone-refractory prostate cancer, as well as other neoplastic diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 31-35 |
| Number of pages | 5 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 38 |
| Issue number | 1 |
| Publication status | Published - 2011 Jan |
Keywords
- CTLA-4
- Clinical trial
- Fully human monoclonal antibody
- Melanoma
ASJC Scopus subject areas
- Oncology
- Cancer Research
